Navigation Links
Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
Date:1/4/2011

ROCHESTER, N.Y., Jan. 4, 2011 /PRNewswire/ -- Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO)

VX15/2503 is a novel humanized antibody that blocks the activity of semaphorin 4D (SEMA4D).  It is the first of two of the Company's therapeutic antibodies expected to begin clinical trials this year. "Advancing VX15 into the clinical stage of development is an exciting achievement for Vaccinex, and a testament to the experience and outstanding capabilities of our research and development teams," said Ray Watkins, Senior Vice President and Chief Operating Officer of the company.

"SEMA4D is an exciting therapeutic target with remarkable biological properties relevant to several disease processes," said Dr. Maurice Zauderer, President and Chief Executive Officer of Vaccinex.  As reflected in its name, semaphorin, the molecule guides the activation and movement of different cell types in different ways.  For example, SEMA4D promotes migration of tumor cells that metastasize to new locations as well as the outgrowth of cells that form new blood vessels required to provide nutrients and energy to tumors.  It is anticipated that, by blocking this signal, the anti-SEMA4D antibody will both inhibit the growth of primary tumors and limit metastases to new sites.  "This is important," Dr. Zauderer said, "because if tumors did not metastasize, then surgeons could cure cancer."  In other tissues and disease processes, for example damage to neurons in demyelinating diseases such as multiple sclerosis (MS)
'/>"/>

SOURCE Vaccinex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
2. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
3. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
4. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
5. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
6. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
7. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
8. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
9. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Eckert ... Accelerator Mass Spectrometry (AMS) services to the pharmaceutical and ... has joined the company in the position of Director ... years of broad and valuable experience in drug metabolism ...
(Date:1/22/2015)... January 21, 2015 Cambridge Semantics, the leading ... today announced that 2014 was a record-breaking year across the ... of the Anzo Smart Data Platform and our Smart Data ... insights from diverse data which led to record growth for ...
(Date:1/22/2015)... zFlo Motion , a US leader ... exciting product from a new partner. STT-Systems has ... past 15 years, with offerings in the optical-motion capture, 3D ... system (inertial measurement unit), iSen, is opening eyes around the ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Sept. 23 Spherix Incorporated (Nasdaq: SPEX ), an ... and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, ... on November 17, 2009, at 9:00 a.m. Eastern time, at the ... , The items of business are: , , ...
... , SAN FRANCISCO, September 23 ... patient has been enrolled in the,Israeli MGuard(TM) Registry. MGuard(TM) ... Cath Lab, managed by Dr. Yitzhak,Herz, the principal investigator ... The Israeli MGuard Registry will enroll 100 ...
... , , RESEARCH TRIANGLE ... CRO, announced a partnership with Max Healthcare to open a Phase ... India. This proof of concept unit will allow Pharmaceutical, Biotech & ... development process across multiple therapeutic areas quickly and with the highest ...
Cached Biology Technology:Spherix Incorporated Announces Annual Shareholders Meeting Date 2Spherix Incorporated Announces Annual Shareholders Meeting Date 3InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 3Max Neeman International to Open Phase I/IIa Unit 2
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an innovative trust ... enhances care coordination among social service and care providers by ... $1 million grant from the Alliance Healthcare Foundation to expand ... recognized as a "Live Well San Diego" partner on December ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... A new study led by University of Kentucky researchers suggests ... the brain. In addition to being essential for maintaining ... roles in other organs and tissue, including the brain. Published ... study showed that middle-aged rats that were fed a diet ...
... initiative, the University,s Institute for Genomic Biology and the ... bringing together top faculty in genomic and computational sciences ... technology for genomic breakthroughs. One human genome is ... 130 encyclopedia-sized books that could take nearly 95 years ...
... new research discovery published in the December 2013 issue ... yields an important clue toward helping curb runaway ... the severity of the inflammatory response and ultimately the ... future benefits for patients with severe asthma, COPD, rheumatoid ...
Cached Biology News:New UK study suggests low vitamin D causes damage to brain 2Illinois initiative creates futuristic facility 2Oxygen levels increase and decrease the effectiveness of anti-inflammatory therapies 2
Complement C1r [Human]...
... designs oligos for SYBR Green, TaqMan, LNA ... FRET assays. Highly specific primers are designed ... interpreting BLAST search results. Primer efficiency is ... by connecting to the Mfold server. Beacon ...
... the LVF-HL, LVF-CUVADPT, FHS-LVF, and the CVD-Diffuse ... low-pass Linear Variable Filters to create the ... center wavelength and adjustable bandpass. Each filter ... blocking band (99.8%). These filters -- ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: